

Frank Hoentjen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10074257/publications.pdf>

Version: 2024-02-01

141
papers

3,288
citations

218677

26
h-index

182427

51
g-index

143
all docs

143
docs citations

143
times ranked

4236
citing authors

#	ARTICLE	IF	CITATIONS
1	Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 182-191.e2.	4.4	17
2	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 689-699.	1.9	9
3	Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 699-706.	2.4	5
4	Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1813-1820.	1.9	5
5	Editorial: <sc>anti-TNF</sc> combination therapy for inflammatory bowel diseaseâ€œone size does not fit all. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 750-751.	3.7	0
6	De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	1.6	2
7	Increased Colorectal Neoplasia Risk in Patients with Inflammatory Bowel Disease and Serrated Polyps with Dysplasia. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5647-5656.	2.3	5
8	Indications, Postoperative Management, and Long-term Prognosis of Crohnâ€™s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. <i>Inflammatory Bowel Diseases</i> , 2022, 28, S16-S24.	1.9	2
9	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	1.3	5
10	Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 597-599.	0.9	5
11	Confirming effectiveness of endoscopic colon cancer screening in IBD: the puzzle remains unsolved?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
12	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohnâ€™s Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5.	4.4	20
13	Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohnâ€™s Disease Patients: A Case Report and Review of the Literature. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 162-164.	1.3	3
14	Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 529-539.	1.3	60
15	Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. <i>Gut</i> , 2021, 70, 1266-1274.	12.1	40
16	Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 520-524.	1.9	7
17	Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 155-161.	1.5	18
18	Reduction in Inflammatory Bowel Disease Healthcare During the Coronavirus Disease 2019 Pandemic: A Nationwide Retrospective Cohort Study. <i>Gastroenterology</i> , 2021, 160, 935-937.e1.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. <i>Annals of Surgery</i> , 2021, 273, 557-563.	4.2	21
20	Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry. <i>Drug Safety</i> , 2021, 44, 581-588.	3.2	13
21	Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1954-1962.	1.9	17
22	Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1920-1930.	1.3	22
23	Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 160, 1584-1598.	1.3	113
24	WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. <i>World Journal of Emergency Surgery</i> , 2021, 16, 23.	5.0	29
25	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394.	2.0	2
26	Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients. <i>Gastroenterology</i> , 2021, 160, 1970-1985.	1.3	31
27	Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy. <i>United European Gastroenterology Journal</i> , 2021, 9, 919-928.	3.8	12
28	Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e783-e788.	1.6	5
29	Letter: tofacitinib in treatment-refractory ulcerative colitis—a single centre real-world experience in Australia. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 534-535.	3.7	0
30	Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor- α during pregnancy: A systemic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2021, 122, 102676.	6.5	13
31	Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	0
32	Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. <i>United European Gastroenterology Journal</i> , 2021, 9, 1136-1147.	3.8	24
33	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. <i>Frontiers in Immunology</i> , 2021, 12, 768957.	4.8	22
34	Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 33-45.	1.3	124
35	Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1060-1067.	1.9	3
36	Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1189-1199.	4.7	24

#	ARTICLE	IF	CITATIONS
37	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 480-489.	1.3	26
38	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti- α TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138.	3.7	87
39	No Increased Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease and Postinflammatory Polyps. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1383-1389.	1.9	15
40	Increased risk of high-grade dysplasia and colorectal cancer in inflammatory bowel disease patients with recurrent low-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 1334-1342.e1.	1.0	8
41	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2020, 382, 92-94.	27.0	6
42	Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti- α TNF failure- "getting closer to the truth. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1255-1256.	3.7	1
43	Mo1818 COLORECTAL NEOPLASIA RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND SERRATED LESIONS. <i>Gastroenterology</i> , 2020, 158, S-936.	1.3	0
44	Stakeholders'™ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1521-1528.	2.4	2
45	Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease- "what about mucosal healing and biomarkers? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 753-754.	3.7	0
46	Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. <i>United European Gastroenterology Journal</i> , 2020, 8, 1031-1044.	3.8	18
47	Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease- "a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1366-1376.	3.7	28
48	Sa1742 THIOGUANINE AND LOW DOSE THIOPURINES AND ALLOPURINOL ARE BOTH SAFE OPTIONS AFTER FAILURE OF CONVENTIONAL THIOPURINES: A COMPARATIVE ANALYSIS OF TWO MULTICENTER COHORTS. <i>Gastroenterology</i> , 2020, 158, S-405.	1.3	0
49	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925.	3.2	20
50	Effectiveness of ustekinumab dose escalation in Crohn's™ disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 135-142.	3.7	51
51	Noninferiority or Nonsuperiority?. <i>Gastroenterology</i> , 2020, 159, 2248.	1.3	0
52	Immune-mediated inflammatory disease patients'™ preferences in adverse drug reaction information regarding biologics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1049-1054.	2.4	6
53	Type C Mucosa in Pouch Surveillance: How Real is the Risk?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1180-1180.	1.3	1
54	A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1076-1086.	3.7	18

#	ARTICLE	IF	CITATIONS
55	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 880-888.	3.7	64
56	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 123-134.	3.7	92
57	Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 465-471.	0.9	14
58	Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 431-440.	0.9	15
59	Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1617-1618.	3.7	0
60	Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 568-570.	4.4	15
61	Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 377-384.	1.9	21
62	Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 172-179.	1.9	24
63	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	1.3	86
64	Su1837 " Higher Discontinuation Rates of Anti-TNF Therapy in Elderly IBD Patients Compared to a Younger Age Group: Results from a Prospective Registry. <i>Gastroenterology</i> , 2019, 156, S-629.	1.3	0
65	Mo1845 " Increased Risk of Advanced Neoplasia in Inflammatory Bowel Disease Patients with Recurrent Low-Grade Dysplasia. <i>Gastroenterology</i> , 2019, 156, S-859.	1.3	0
66	Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1485-1491.	1.3	28
67	Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1293-1300.	3.7	6
68	Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. <i>Gut</i> , 2019, 68, 615-622.	12.1	27
69	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1558-1565.	1.9	7
70	Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1298-1306.	1.9	53
71	TNF- α -induced protein 3 (TNFAIP3) /A20 acts as a master switch in TNF- α blockade-driven IL-17A expression. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 517-529.	2.9	52
72	Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 425-431.	1.3	24

#	ARTICLE	IF	CITATIONS
73	Urinalysis of MMXâ€mesalazine as a tool to monitor 5â€ASA adherence in daily IBD practice. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 477-481.	2.4	5
74	Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2015-2026.	1.9	14
75	Short article: Recommendations on rectal surveillance for colorectal cancer after subtotal colectomy in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 843-846.	1.6	5
76	Sa1738 - Thiopurines Versus Anti-TNFÎ± for the Prevention of Postoperative Recurrence in Crohn's Disease - A Metaanalysis. <i>Gastroenterology</i> , 2018, 154, S-375-S-376.	1.3	0
77	Mo1884 - Drug Survival of Vedolizumab-Treated Inflammatory Bowel Disease Patients in a Nationwide Observational Cohort Study: ICC Case Series. <i>Gastroenterology</i> , 2018, 154, S-838.	1.3	0
78	162 - Long-Term Risk of Advanced Neoplasia after Colonic Low-Grade Dysplasia in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Gastroenterology</i> , 2018, 154, S-45.	1.3	0
79	Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade Â® to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study. <i>Gastroenterology</i> , 2018, 154, S-822.	1.3	0
80	Mo1896 - Ustekinumab for Crohn's Disease: A Nationwide Real-Life Observational Cohort Study (ICC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.3	1
81	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. <i>Nature Communications</i> , 2018, 9, 2427.	12.8	159
82	Clinical experience and diagnostic algorithm of vulval Crohnâ€™s disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 838-843.	1.6	21
83	Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2018-2026.	1.9	19
84	Switching From RemicadeÃ¢Â® to Biosimilar ct-P13 in Inflammatory Bowel Disease Patients: One Year Follow-Up of a Prospective Observational Cohort Study. <i>Gastroenterology</i> , 2017, 152, S587.	1.3	0
85	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. <i>BMJ Open</i> , 2017, 7, e016695.	1.9	33
86	Long-Term Clinical Outcomes After Switching from RemicadeÂ® to Biosimilar CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3117-3122.	2.3	61
87	Colorectal Cancer Risk in Patients With Lynch Syndrome and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 454-458.e1.	4.4	20
88	Is the prevalence of colonic neuroendocrine tumors increased in patients with inflammatory bowel disease?. <i>International Journal of Cancer</i> , 2016, 139, 535-542.	5.1	11
89	Controversies in Pouch Surveillance for Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 747-751.	1.3	16
90	Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. <i>Acta OncolÃ³gica</i> , 2016, 55, 444-448.	1.8	6

#	ARTICLE	IF	CITATIONS
91	Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1287-1293.	1.3	124
92	Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 177-179.	1.2	5
93	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	1.3	85
94	Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 159-165.	1.3	13
95	Probiotics and prebiotics in ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 55-71.	2.4	92
96	Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 798-806.e20.	4.4	68
97	Epstein-Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 398-403.	1.3	70
98	Su1307 Neoplasia Risk After Colectomy in Inflammatory Bowel Disease Patients - A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2015, 148, S-469.	1.3	0
99	Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro. <i>Cell Biology and Toxicology</i> , 2015, 31, 161-171.	5.3	13
100	LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease. <i>PLoS ONE</i> , 2015, 10, e0133932.	2.5	8
101	Better survival of renal cell carcinoma in patients with inflammatory bowel disease. <i>Oncotarget</i> , 2015, 6, 38336-38347.	1.8	14
102	A biopsy-guided analysis of diarrhea in patients treated with tyrosine kinase inhibitors of the vascular endothelial growth factor receptor.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15596-e15596.	1.6	0
103	Golimumab for the treatment of ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 53.	2.3	22
104	Management of Crohn's disease in poor responders to adalimumab. <i>Clinical and Experimental Gastroenterology</i> , 2014, 7, 83.	2.3	5
105	Allopurinol-thiopurine combination therapy in inflammatory bowel disease. <i>Clinical Investigation</i> , 2014, 4, 873-879.	0.0	1
106	Severe exacerbation of Crohn's disease during sunitinib treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 234-236.	1.6	7
107	Mo1669 Renal Cell Carcinoma Patients Have a Better Survival in a Nationwide Inflammatory Bowel Disease Cohort Compared With the General Population. <i>Gastroenterology</i> , 2014, 146, S-631-S-632.	1.3	0
108	Tu1936 Case-Control Study and Meta-Analysis of Glutathione S-Transferase Polymorphisms in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, S-876.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Prior Colorectal Neoplasia Is Associated With Increased Risk of Ileoanal Pouch Neoplasia in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2014, 146, 119-128.e1.	1.3	113
110	GST Theta null genotype is associated with an increased risk for ulcerative colitis: a caseâ€“control study and meta-analysis of GST Mu and GST Theta polymorphisms in inflammatory bowel disease. <i>Journal of Human Genetics</i> , 2014, 59, 575-580.	2.3	10
111	Su1114 Intestinal Epstein-Barr Virus Is Associated With Mucosal Lymphoproliferation and Subsequent Intestinal Surgery in Inflammatory Bowel Disease Patients. <i>Gastroenterology</i> , 2014, 146, S-378-S-379.	1.3	0
112	Mo1190 Co-Administration of 5-Aminosalicylic Acid to 6-Mercaptopurine Reduces In Vitro Hepatotoxicity. <i>Gastroenterology</i> , 2014, 146, S-582.	1.3	0
113	Mo1196 In Vitro Pancreas Toxicity by Azathioprine but Not 6-Mercaptopurine. <i>Gastroenterology</i> , 2014, 146, S-583.	1.3	0
114	Cuff and Pouch Cancer in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, E20.	1.9	0
115	Safety and Effectiveness of Long-term Allopurinolâ€“Thiopurine Maintenance Treatment in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 363-369.	1.9	89
116	Long-term Treatment of Patients With a History of Ulcerative Colitis Who Develop Gastritis and Pan-Enteritis After Colectomy. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 52-57.	2.2	27
117	Elective Switching from Infliximab to Adalimumab in Stable Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 761-766.	1.9	15
118	Complications of Peristomal Recurrence of Crohn's Disease. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2012, 39, 297-301.	1.0	14
119	268 An Elective Switch From Infliximab to Adalimumab in Quiescent Crohn's Disease is Safe and Effective. <i>Gastroenterology</i> , 2012, 142, S-64.	1.3	0
120	Infectious Proctitis: When to Suspect It Is Not Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 269-273.	2.3	76
121	Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction. <i>Digestive Diseases and Sciences</i> , 2012, 57, 250-253.	2.3	8
122	Biologic Therapy of Crohn's Disease: Infliximab. , 2012, , 413-432.		0
123	Update on the Management of Ulcerative Colitis. <i>Current Gastroenterology Reports</i> , 2011, 13, 475-485.	2.5	18
124	Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction. <i>American Journal of Gastroenterology</i> , 2011, 106, S354.	0.4	0
125	Pan-enteritis in Patients with a History of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2011, 106, S353-S354.	0.4	0
126	Long-term Effectiveness and Tolerability of Allopurinol and Thiopurine Combination Therapy in Inflammatory Bowel Disease Patients: 2011 ACG IBD Award. <i>American Journal of Gastroenterology</i> , 2011, 106, S438-S439.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2067.	3.3	100
128	Pathophysiology of Inflammatory Bowel Diseases. , 2008, , 341-373.		2
129	CD4+ T lymphocytes mediate colitis in HLA-B27 transgenic rats monoassociated with nonpathogenic <i>Bacteroides vulgatus</i> . <i>Inflammatory Bowel Diseases</i> , 2007, 13, 317-324.	1.9	21
130	STAT3 regulates NF- κ B recruitment to the IL-12p40 promoter in dendritic cells. <i>Blood</i> , 2005, 105, 689-696.	1.4	145
131	Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis. <i>Immunology</i> , 2005, 116, 112-121.	4.4	21
132	Reduction of Colitis by Prebiotics in HLA-B27 Transgenic Rats Is Associated with Microflora Changes and Immunomodulation. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 977-985.	1.9	179
133	Adenosine is a negative regulator of NF- κ B and MAPK signaling in human intestinal epithelial cells. <i>Cellular Immunology</i> , 2005, 237, 86-95.	3.0	28
134	Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. , 2005, , 681-701.		17
135	Dysregulated luminal bacterial antigen-specific T cell responses and antigen presenting cell function in HLA-B27 transgenic rats with chronic colitis. <i>Gastroenterology</i> , 2003, 124, A487.	1.3	1
136	B cells produce immunoregulatory molecules in both HLA-B27 transgenic rats with colitis and non-transgenic littermates. <i>Gastroenterology</i> , 2003, 124, A487.	1.3	0
137	Effect of circulating peptide YY on gallbladder motility in response to feeding in humans. <i>Gastroenterology</i> , 2001, 120, A14.	1.3	1
138	Different cytokine profiles in mesenteric lymph node cells from HLA-B27 transgenic versus wild type rats stimulated with cecal bacterial antigen. <i>Gastroenterology</i> , 2001, 120, A516.	1.3	0
139	Antibiotics with a selective aerobic and anaerobic spectrum have different therapeutic activities in various regions of the colon in IL-10 knock-out mice. <i>Gastroenterology</i> , 2001, 120, A687.	1.3	1
140	Digestive Disease Week 2011: An Update on IBD Clinical Research. <i>International Journal of Clinical Reviews</i> , 0, , .	0.1	0
141	Update on Conventional Thiopurine Management in IBD. <i>International Journal of Clinical Reviews</i> , 0, , .	0.1	0